Investigating how certain enzymes affect cancer treatment
Mechanistic Studies of Type II Topoisomerases and Topoisomerase-Targeted Agents
This study is looking at how certain enzymes help manage DNA in our cells and how we can use this knowledge to create better cancer treatments, which could help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-10983800 on NIH RePORTER |
What this research studies
This research focuses on type II topoisomerases, enzymes that play a crucial role in DNA processes such as replication and repair. By understanding how these enzymes function and how they can be targeted by anti-cancer drugs, the research aims to improve cancer therapies. The approach involves studying the mechanisms by which these enzymes create DNA breaks that can lead to cell death in cancerous cells. Patients may benefit from insights gained that could lead to more effective cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that are treated with drugs targeting type II topoisomerases, such as acute lymphoblastic leukemia or acute promyelocytic leukemia.
Not a fit: Patients with cancers that do not involve type II topoisomerases or those who are not receiving treatment that targets these enzymes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments that are more effective and have fewer side effects.
How similar studies have performed: Previous research has shown success in targeting topoisomerases for cancer treatment, indicating that this approach has potential for further advancements.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Osheroff, Neil — Vanderbilt University
- Study coordinator: Osheroff, Neil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.